Top

Clinical Research in Cardiology

Published in:

01-07-2018 | Letter to the Editors

Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertension

Authors: Martin Steinmetz, Dominik Nelles, Jutta Weisser-Thomas, Christian Schaefer, Georg Nickenig, Nikos Werner

Published in: Clinical Research in Cardiology | Issue 7/2018

Excerpt

Sirs: …

Cai A, Feng Y, Zhou Y (2017) A comprehensive review of an unmet public health issue: resistant hypertension. Clin Exp Hypertens 39:101–107. https://doi.org/10.1080/10641963.2016.1226892 CrossRefPubMed

Cecchi E, Parodi G, Fatucchi S et al (2016) Prevalence of thrombophilic disorders in takotsubo patients: the (ThROmbophylia in TAkotsubo cardiomyopathy) TROTA study. Clin Res Cardiol 105:717–726. https://doi.org/10.1007/s00392-016-0977-x CrossRefPubMed

Vegter EL, Ovchinnikova ES, van Veldhuisen DJ et al (2017) Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. Clin Res Cardiol 106:598–609. https://doi.org/10.1007/s00392-017-1096-z CrossRefPubMedPubMedCentral

Völz S, Svedlund S, Andersson B et al (2017) Coronary flow reserve in patients with resistant hypertension. Clin Res Cardiol 106:151–157. https://doi.org/10.1007/s00392-016-1043-4 CrossRefPubMed

Bhatt DL, Kandzari DE, O’Neill WW et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401. https://doi.org/10.1056/NEJMoa1402670 CrossRefPubMed

Fengler K, Rommel KP, Okon T et al (2016) Renal sympathetic denervation in therapy resistant hypertension—pathophysiological aspects and predictors for treatment success. World J Cardiol 8:436–446. https://doi.org/10.4330/wjc.v8.i8.436 CrossRefPubMedPubMedCentral

Tsioufis C, Ziakas A, Dimitriadis K et al (2017) Erratum to: Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry (Clin Res Cardiol, 10.1007/s00392-016-1056-z). Clin Res Cardiol 106:392. https://doi.org/10.1007/s00392-017-1084-3 CrossRefPubMed

Kulenthiran S, Ewen S, Böhm M, Mahfoud F (2017) Hypertension up to date: SPRINT to SPYRAL. Clin Res Cardiol 106:475–484. https://doi.org/10.1007/s00392-017-1095-0 CrossRefPubMed

Ott C, Kopp C, Dahlmann A et al (2018) Impact of renal denervation on tissue Na+ content in treatment-resistant hypertension. Clin Res Cardiol 107:42–48. https://doi.org/10.1007/s00392-017-1156-4 CrossRefPubMed

10.

Persu A, Jin Y, Baelen M et al (2014) Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 63:1319–1325. https://doi.org/10.1161/HYPERTENSIONAHA.114.03194 CrossRefPubMed

11.

Prado JC, Salado D, Ruilope LM, Segura J (2016) Second denervation in a patient with resistant hypertension. Clin Res Cardiol 105:880–883. https://doi.org/10.1007/s00392-016-0997-6 CrossRefPubMed

12.

Lu D, Wang K, Liu Q et al (2016) Reductions of left ventricular mass and atrial size following renal denervation: a meta-analysis. Clin Res Cardiol 105:648–656. https://doi.org/10.1007/s00392-016-0964-2 CrossRefPubMed

13.

Sharp ASP, Davies JE, Lobo MD et al (2016) Renal artery sympathetic denervation: observations from the UK experience. Clin Res Cardiol 105:544–552. https://doi.org/10.1007/s00392-015-0959-4 CrossRefPubMedPubMedCentral

14.

Fengler K, Heinemann D, Okon T et al (2016) Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clin Res Cardiol 105:592–600. https://doi.org/10.1007/s00392-015-0955-8 CrossRefPubMed

15.

Donazzan L, Mahfoud F, Ewen S et al (2016) Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clin Res Cardiol 105:364–371. https://doi.org/10.1007/s00392-015-0930-4 CrossRefPubMed

16.

Schumacher K, Dagres N, Hindricks G et al (2017) Characteristics of PR interval as predictor for atrial fibrillation: association with biomarkers and outcomes. Clin Res Cardiol 106:767–775. https://doi.org/10.1007/s00392-017-1109-y CrossRefPubMed

17.

Townsend RR, Mahfoud F, Kandzari DE et al (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. https://doi.org/10.1016/S0140-6736(17)32281-X CrossRefPubMed

18.

Mahfoud F, Schmieder RE, Azizi M et al (2017) Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future. Eur Heart J 38:3272–3281a. https://doi.org/10.1093/eurheartj/ehx215 CrossRefPubMedPubMedCentral

19.

Hijmering ML, Stroes ESG, Olijhoek J et al (2002) Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 39:683–688. https://doi.org/10.1016/S0735-1097(01)01786-7 CrossRefPubMed

20.

Mueller C, Wodack K, Twelker K et al (2011) Darbepoetin improves endothelial function and increases circulating endothelial progenitor cell number in patients with coronary artery disease. Heart 97:1474–1478. https://doi.org/10.1136/hrt.2010.220798 CrossRefPubMed

21.

Gosse P, Cremer A, Pereira H et al (2017) Twenty-four-hour blood pressure monitoring to predict and assess impact of renal denervation. Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.116.08448 CrossRefPubMed

22.

Wang Y (2014) Is isolated systolic hypertension an indication for renal denervation? Front Physiol 5:1393–1401. https://doi.org/10.3389/fphys.2014.00505 CrossRef

23.

Eikelis N, Hering D, Marusic P et al (2015) The effect of renal denervation on endothelial function and inflammatory markers in patients with resistant hypertension. Int J Cardiol 188:96–98. https://doi.org/10.1016/j.ijcard.2015.04.041 CrossRefPubMed

24.

Dörr O, Liebetrau C, Möllmann H et al (2014) Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (Intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension 63:984–990. https://doi.org/10.1161/HYPERTENSIONAHA.113.02266 CrossRefPubMed

Title: Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertension
Authors: Martin Steinmetz
Dominik Nelles
Jutta Weisser-Thomas
Christian Schaefer
Georg Nickenig
Nikos Werner
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 7/2018
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-018-1236-0

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertension

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2018

Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany

Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF

First experience with zero-fluoroscopic ablation for supraventricular tachycardias using a novel impedance and magnetic-field-based mapping system

Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data

Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design

Impact of pannus formation on hemodynamic dysfunction of prosthetic aortic valve: pannus extent and its relationship to prosthetic valve motion and degree of stenosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page